Status:
COMPLETED
CoVID-19 Plasma in Treatment of COVID-19 Patients
Lead Sponsor:
The Christ Hospital
Conditions:
COVID 19
Eligibility:
All Genders
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
The investigatores propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in patients requiring hospitalization for symptomatic "high risk" COVID19 ...
Detailed Description
Coronavirus's are responsible for 15-30% of "common colds" and approximately 2% of the population may be healthy carriers of these viruses. The ongoing SARS CoV-2 pandemic originated in Wuhan, Hubei, ...
Eligibility Criteria
Inclusion
- Age 18-80 years
- Symptomatic CoVID-19 disease requiring hospitalization
- SARS-CoV-19 PCR positive
- Elevated hsTPN
Exclusion
- Multi-organ / system failure
- Renal insufficiency (eGFR \<30 or renal replacement therapy)
- Liver dysfunction (\>3x ULN SGOT / SGPT)
- Chronic Immunosuppression therapy
- Prior organ transplant
- Prior multiple transfusions for Myelodysplastic syndrome
- Prior treatment with plasma, immunoglobulin transfusion within 30 days
- Allergic reaction to blood/ plasma products
- Pregnant or breast feeding at the time of study
- Inability to provide informed consent
Key Trial Info
Start Date :
April 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 12 2020
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04355897
Start Date
April 28 2020
End Date
August 12 2020
Last Update
January 5 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The Christ Hospital
Cincinnati, Ohio, United States, 45219
2
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106